![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 42, 29744-29748, October 15, 1999
From the Department of Molecular Cell Biology, Leiden University
Medical Centre, Wassenaarseweg 72, 2333 AL Leiden, The Netherlands
Cells harboring patient-derived mitochondria with
an A-to-G transition at nucleotide position 3243 of their mitochondrial DNA display severe loss of respiration when compared with cells containing the wild-type adenine but otherwise identical mitochondrial DNA sequence. The amount and degree of leucylation of
tRNALeu(UUR) were both found to be highly
reduced in mutant cells. Despite the low level of
leucyl-tRNALeu(UUR), the rate of mitochondrial
translation was not seriously affected by this mutation. Therefore,
decrease of mitochondrial protein synthesis as such does not appear to
be a necessary prerequisite for loss of respiration. Rather, the
mitochondrially encoded proteins seem subject to elevated degradation,
leading to a severe reduction in their steady state levels. Our results
favor a scheme in which the 3243 mutation causes loss of respiration
through accelerated protein degradation, leading to a disequilibrium
between the levels of mitochondrial and nuclear encoded respiratory
chain subunits and thereby a reduction of functional respiratory chain
complexes. The possible mechanisms underlying the pathogenesis of
mitochondrial diabetes is discussed.
Nucleotide substitutions in the mitochondrial tRNA genes are
important factors in the pathogenesis of several multisystem disorders
including mitochondrial encephalomyopathies and maternally inherited
diabetes and deafness (MIDD)1
(1-6). A point mutation in the structural gene for a tRNA may be
expected to influence protein synthesis either quantitatively or
qualitatively. A strong reduction in mitochondrial protein synthesis,
in particular in the proteins with a high lysine content, has been
reported in the case of the 8344 mutation in the tRNALys
gene of myoclonus epilepsy with ragged red fibers (MERRF). This reduction is thought to be caused by the premature termination of
mitochondrial translation on lysine codons and the subsequent formation
of truncated polypeptides (7). Mitochondrial protein synthesis has also
been found decreased in the case of the 3243 mutation associated with
mitochondrial myopathy, encephalopathy, lactic acidosis, and
stroke-like episodes (MELAS) (8, 9). Therefore, the general view has
emerged that mutations in tRNA genes cause mitochondrial dysfunction by
lowering mitochondrial protein synthesis and, as a consequence, the
amount of mitochondrially encoded respiratory chain enzymes. Indeed,
mitochondrial respiration is severely reduced in these cases (7-9).
However, the large variation in clinical phenotypes that associate with
tRNA mutations is difficult to explain solely by the lowered
respiration rate.
MIDD accounts for 1-2% of the diabetic population in Europe and Japan
and is clinically characterized by an early middle age onset of
diabetes and sensorineural hearing loss, progressive insulin secretory
defect, absence of islet cell antibodies, and absence of obesity (10,
11). As a first step in understanding the molecular mechanisms caused
by the 3243 mutation, we have established mitochondrial transformants
(cybrids) carrying either the wild-type adenine or the mutant-type
guanine at position 3243 but having otherwise identical mitochondrial
DNA sequences (12). Care was taken to ensure that all cell lines
contained high and comparable mitochondrial DNA copy numbers. The
mutant-type cells displayed a severe reduction of cellular respiration
and respiratory chain activity, which has provided proof for the
pathogenicity of the 3243 mutation in MIDD (12). In the present work,
the analysis of these cybrids has been extended toward mitochondrial tRNA and protein metabolism in order to understand better the molecular
mechanisms leading from the 3243 mutation to impaired respiration and
MIDD.
Cell Culture--
The mitochondrial transformants (cybrids) used
in this study had been generated earlier by the transfer of
mitochondria from two genetically unrelated diabetes patients (V and A)
into mitochondrial DNA-less B Oxygen Consumption--
The rate of oxygen consumption by
~5 × 106 exponentially growing cells in 2 ml of
complete DMEM but without glucose was measured at 37 °C using a
Clark-type electrode as described (14).
Northern Blot Analysis--
Total RNA (20 µg), isolated from
exponentially growing cells by the guanidinium thiocyanate method (15),
was subjected to electrophoresis through a 1% agarose-formaldehyde
gel, transferred onto Hybond N+ membranes and hybridized
overnight at 42 °C with 32P-labeled probes specific for
the tRNALeu(UUR) gene (nucleotides 3245-3861) or the
tRNAPhe gene (nucleotides 245-706), and washed with
several changes of 1× SSC, 0.5% SDS at 42 °C (16). tRNA bands were
visualized by autoradiography and quantified using PhosphorImager
detection and ImageQuant analysis.
The degree of in vivo aminoacylation of tRNAs was determined
by high-resolution electrophoresis and subsequent Northern analysis as
described (17). To prevent deacylation of tRNA during isolation, RNA
was isolated under acidic conditions by the guanidinium thiocyanate method (15) but using 0.15 M sodium acetate, pH 4.0, instead of pH 7 buffers throughout. The final RNA preparation was
dissolved in 10 mM sodium acetate, pH 4.0.
Mitochondrial Protein Synthesis and
Degradation--
[35S]Methionine incorporation into
mitochondrially encoded proteins was analyzed on SDS-polyacrylamide
gels essentially as described (18). In brief, ~5 × 105 exponentially growing cells in a 3.4-cm dish were
washed twice with methionine-free DMEM and incubated for 30 min at
37 °C with Promix (a 2:1 mixture of [35S]methionine
and [35S]cysteine from Amersham Pharmacia Biotech; 10 µCi/µl, 1,000 Ci/mmol) in 0.75 ml of methionine-free DMEM
supplemented with 10% dialysed fetal bovine serum and emetine (100 µg/ml), which was added 15 min before the addition of label.
The cells were washed three times with phosphate-buffered saline and
finally dissolved in 100 µl of SDS sample buffer. Samples (40 µg)
were analyzed on 15% SDS-polyacrylamide gels. Mitochondrial
translation products were assigned according to Chomyn et
al. (18). Protein concentration was determined by the
bicinchoninic acid assay (Pierce).
In the case of [3H]leucine incorporation,
[35S]methionine was replaced by
L-[4,5-3H]leucine (10 µCi/0.75 ml on a
3.4-cm dish; 68 Ci/mmol) in leucine-free complete DMEM. After the
specified incubation period, the ~5 × 105 cells
were washed three times with phosphate-buffered saline and dissolved in
0.5 ml of 0.1 M NaOH. 100-µl aliquots were immediately withdrawn in duplicate, added to 100 µl of cold 20% trichloroacetic acid, and heated for 10 min at 90 °C. The precipitate was collected on a glass fiber filter, washed, and counted as described (19). The
significance of the differences between wild-type and mutant-type incorporation was estimated by linear regression analysis using SPSS
7.0 software (Chicago).
The protein degradation rate of individual mitochondrial proteins was
estimated from pulse-chase experiments (20). For pulse values,
~5 × 105 cells (pretreated with chloramphenicol)
were incubated for 2 h at 37 °C with Promix and the reversible
cytoplasmic protein synthesis inhibitor cycloheximide (200 µg/ml)
instead of emetine and washed three times with phosphate-buffered
saline. For chase values, the pulsed cells were washed with complete
DMEM instead of phosphate-buffered saline and subsequently cultured for
48 h in complete DMEM with two daily changes of medium. The decay rate constant, Western Blotting and Immunoprecipitation--
Western blotting
was performed essentially as described (21). In brief, total cellular
protein was separated on a 15% SDS gel and transferred to a
polyvinylidene difluoride membrane (Immobilon P, Millipore).
Subsequently, the proteins were specifically visualized using
monoclonal antibodies against cytochrome c oxidase subunits I, II, and IV (Molecular Probes) and enhanced chemiluminescence (Amersham Pharmacia Bitotech).
Immunoprecipitates (22) were prepared by a 16-h incubation at 0 °C
of mitochondria-enriched fractions (35 µg) (20) with monoclonal
antibody (2 µg) and protein G-Sepharose (10 µl) (Amersham Pharmacia
Biotech) in 0.5 ml of 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 1% Triton X-100. The beads were washed twice
with the same buffer and twice with 5 mM Tris-HCl, pH 7.5, and were then suspended in SDS sample buffer. The composition of the
eluted proteins was analyzed by SDS-polyacrylamide gel electrophoresis followed by autoradiography.
Oxygen Consumption--
Stable mitochondrial transformants
containing wild-type or mutant-type mitochondrial DNA have been
generated and characterized earlier (12). Cybrids were cultured on
selective media to obtain and preserve high and comparable
mitochondrial DNA copy numbers. Mutant-type cybrids displayed an
~5-fold reduced rate of respiration (Fig.
1) and a 79-98% reduction of individual
respiratory chain enzymes (12).
Steady State Level of tRNA--
Northern blot analysis revealed
that the level of tRNALeu(UUR) in the mutant-type cells was
reduced to ~25% of the level found in wild-type cybrids or the
parental 143B cells, whereas the amount of tRNAPhe remained
constant within this set of cybrids (Fig.
2A). The relative ratio of
tRNALeu(UUR) to tRNAPhe was estimated to be
0.19 ± 0.05 for the mutant-type and 0.80 ± 0.12 for the
wild-type cybrids. Furthermore, there was no change observed in the
level of mature ND1, 12 S, and 16 S rRNA transcripts. "RNA19"
however, which represents an unspliced transcript encompassing 16 S
rRNA, tRNALeu(UUR), and the ND1 mRNA, was increased in
the mutant-type cells (not shown) comparable with the results
previously described for the MELAS 3243 cybrids (9).
Aminoacylation of tRNA--
To determine whether the 3243 mutation also affects the degree of aminoacylation of
tRNALeu(UUR), we examined the ratio of
mitochondrial leucyl-tRNALeu(UUR) and non-acylated
tRNALeu(UUR) in wild-type versus
mutant-type cybrids. RNA was isolated under acidic conditions to
prevent deacylation and analyzed on an acidic urea gel followed by
Northern blotting (17). Because aminoacylation results in a lowered
mobility of most tRNAs, this method allows the resolution and
quantitation of both forms. The in vivo degree of
aminoacylation of tRNALeu(UUR) was found to be reduced from
~75% leucylation in wild-type cells to ~40% in all of the
mutant-type cybrids (Fig. 2B). In contrast, tRNALys showed a more constant level of ~80%
aminoacylation in both types of cells. Therefore, when taking into
account the reduced steady state level of tRNALeu(UUR), the
amount of aminoacylated leucyl-tRNALeu(UUR) available for
mitochondrial protein synthesis is very low in mutant-type cells and is
estimated to be ~15% of the wild-type level.
Mitochondrial Protein Synthesis--
Because all mitochondrial
mRNAs contain a number of UUR codons, it may be expected that a low
level of leucyl-tRNALeu(UUR) would reduce the rate of
mitochondrial translation, at least when
leucyl-tRNALeu(UUR) is a limiting factor for mitochondrial
protein synthesis. Therefore, we estimated the rate of mitochondrial
protein synthesis by measuring the incorporation of
[35S]methionine into protein in the presence of the
cytoplasmic protein synthesis inhibitor, emetine. Unexpectedly, we did
not observe a severe decrease in the rate of
[35S]methionine incorporation into mitochondrially
encoded proteins (Fig. 3, left
panel). Rather, the overall rate of mitochondrial protein
synthesis of most of the mutant-type cybrids (4 of 5) was very
comparable with that of the wild-type cybrids. The MERRF cybrid, which
was included as a control, did show a sharp decrease in mitochondrial
translation (Fig. 3, right panel) (7, 18). We did not find
in our cybrids a correlation between labeling intensity of a particular
protein and the number of UUR codons in its respective mRNA
(cf. Ref. 7). Remarkably, the synthesis of ATPase subunits,
especially ATPase 8, was strongly enhanced in mutant-type cybrids (Fig.
3, left panel). Furthermore, mutant cells displayed four
additional, but weakly 35S-labeled protein bands (indicated
by arrowheads in Fig. 3, left panel), which may
represent degradation products of the mutant mitochondrial proteins.
The cybrids originating from the MIDD patient were indistinguishable
from that of the patient with Alport-like syndrome, with the exception
of M12, which showed a ~50% reduction of protein synthesis rate.
Because the rate of translation does not seem to be seriously
diminished in most cybrids, the 3243 mutation may possibly affect the
accuracy of mitochondrial protein synthesis by inducing the incorporation of amino acids other than leucine at UUR codons. Therefore, we measured the rate of [3H]leucine
incorporation into mitochondrial protein as a first estimate of the
degree of misincorporation at UUR codons of the mitochondrial
mRNAs. [3H]Leucine incorporation was measured at
various cell densities because we have noticed that the rate of
mitochondrial protein synthesis depends on cell density, probably
reflecting a gradual shutdown of protein synthesis as soon as the cells
become more confluent. Because the mitochondrial genome contains two
leucyl-tRNA genes with UUR as the minor codon for leucine (89 UUR
codons versus 553 for CUN), the maximal difference between
wild-type and mutant-type cybrids is expected to be in the order
15-20%, at least when complete misincorporation occurs at UUR codons.
[3H]Leucine incorporation was indeed slightly (~15%),
but significantly (p < 0.01) lower in mutant-type
versus wild-type cells at all of the cell densities analyzed
(Fig. 4). Therefore, the misincorporation of amino acids at UUR codons seems indicated.
Mitochondrial Protein Degradation--
The rate of mitochondrial
protein degradation was estimated from pulse-chase experiments (20).
After pretreatment with chloramphenicol to stabilize the mitochondrial
proteins after removal of the drug (20), the cybrids were labeled for
2 h with [35S]methionine in the presence of the
reversible cytoplasmic protein synthesis inhibitor cycloheximide. The
decay of 35S during the 48-h period following labeling was
subsequently determined for individual protein bands. The stability of
mitochondrially encoded proteins was found to be slightly but
significantly (p < 0.01) lower in the mutant
versus wild-type cybrids (Fig.
5). Furthermore, the decay rates of
individual mitochondrial proteins are in a remarkably close range,
suggesting that mitochondrial protein turnover be coordinately
regulated.
Western blot analysis revealed a decreased steady state level of the
mitochondrially encoded proteins cytochrome c oxidase subunits I and II, whereas that of the nuclear-encoded mitochondrial proteins cytochrome c oxidase subunit IV and elongation
factor EF-Tu were both found to be comparable in mutant
versus wild-type cybrids (Fig.
6). As may be expected, the
mitochondrially encoded proteins were not present in the mitochondrial
DNA-less B The total gene content of the mitochondrion, 2 rRNA, 22 tRNA, and
13 protein-coding genes, is completely involved in the synthesis of
components for oxidative phosphorylation. Therefore, any mutation in
mitochondrial DNA may be expected to affect mitochondrial respiration in the first instance. Indeed, in the case of most pathogenic mitochondrial DNA mutations, respiration is reduced in near-homoplasmic mutant cells, independent of the nature of mitochondrial DNA mutation. The clinical phenotype related to these mutations, however, varies strongly. For instance, MERRF, which is caused by a mutation in the
tRNALys gene, is a severe neuromuscular disease with a low
life expectancy, whereas MIDD with the tRNALeu mutation
presents as a milder disorder. Furthermore, the same mitochondrial DNA
mutation can even produce distinct clinical phenotypes in different
individuals (6). The latter is especially evident for the 3243 mutation
in the tRNALeu gene, which may lead to MIDD, Alport-like
syndrome, MELAS, or chronic progressive external ophthalmoplegia (12).
This difference in pathogenesis may best be explained by assuming the
involvement of additional nuclear or mitochondrial factors that
determine the spatial and temporal distribution of the 3243 mutation
over the different tissues and thereby determine the organ most
affected. Because tRNA also seems to be involved in processes other
than translation (23), it cannot be ruled out that the mutated tRNA gene product exerts its effect instead via other processes.
We have generated distinct clonal cell lines carrying the 3243 mutation
from patients with MIDD and Alport-like syndrome in a near-homoplasmic
form. The mitochondrial genome from the patient with MIDD has been
extensively sequenced with the only heteroplasmic nucleotide found at
position 3243 (3). Therefore, it may be assumed that upon
mitochondria-mediated transformation the only difference between
wild-type and mutant-type cybrids is the A-to-G transition at position
3243. Contrary to reports on cybrids from MERRF and MELAS patients (7,
8, 18, 24), our mutant-type cybrids show a serious deficiency in
cellular respiration without a strong decrease in the rate of protein
synthesis. The same applies for our mutant-type cybrids derived from
Alport-like syndrome and also for some of the 3243 cybrids isolated in
Dr. H. Jacobs' laboratory (University of
Tampere).2 In this context it should be
mentioned that another panel of cybrids with low copy numbers of
mitochondrial DNA often displayed a serious decrease of mitochondrial
protein synthesis (25). Therefore, we took great care to ensure that
all cell lines contained a high and comparable amount of mitochondrial
DNA (12). Because we have generated cybrids with severe mitochondrial
dysfunction without a strong decrease in protein synthesis rate, it is
evident that a decrease in mitochondrial protein synthesis is not a
necessary prerequisite for mitochondrial dysfunction. Therefore, our
findings call into doubt the belief that a decrease in mitochondrial
protein synthesis is a necessary prerequisite for loss of respiration and induction of pathogenesis. Our data suggest rather that the 3243 mutation reduces the stability of the mitochondrially encoded proteins,
which may be due to misincorporated amino acids at UUR codons of the
mitochondrial mRNAs (Fig. 4). Interestingly, a similar mechanism
has been proposed to occur in SV40 transformed B-cells containing
~70% 3243 mutant mitochondrial DNA (26). Finally, it is important to
mention that our cybrids did not contain a suppressor mutation in the
anti-codon of the tRNALeu(CUN) gene as found recently by
Jacobs and co-workers (27).
The low level of tRNALeu(UUR) itself may be explained by
enhanced susceptibility for degradation as a result of decreased
affinity toward its natural partners, leucyl-tRNA synthetase, EF-Tu, or the ribosome. In this context, it has been postulated that a tRNA is
never free but is always bound to one of these three partners (28). On
the other hand, because RNA19 is elevated, it cannot be ruled out that
the synthesis of the mutated tRNALeu(UUR) is impaired at
the processing level (29). It has been suggested in MERRF disease that
a relative level of ~40% Lys-tRNALys is sufficiently low
to reduce the synthesis of mitochondrial proteins in MERRF cybrids (7).
However, with a level of ~15% Leu-tRNALeu(UUR), we did
not find such dramatic behavior, even though the absolute levels of
tRNALeu(UUR) and tRNALys are quite comparable
in wild-type cells (30). But how should the low level of
leucyl-tRNALeu(UUR) be reconciled with the high rate of
protein synthesis? With the assumption of an elongation rate of 20 amino acids/s/ribosome (31), which corresponds to an average transit
time of 50 ms at each codon, the synthesis of a complete protein of 500 amino acids will require 25 s (500 × 50ms). The ~6-fold
decrease in leucyl-tRNALeu(UUR) may diminish the rate of
elongation at UUR at most by a factor of 6 but probably by less (32).
Thus, the transit time at UUR will rise to 300 ms at the most.
Theoretically, the time to synthesize the complete protein, containing
on average 10 UUR codons, would be elevated to (490 × 50 ms) + (10 × 300 ms) = 27.5 s, which corresponds to a 10%
reduction of the rate of protein synthesis at the most.
The 3243 mutation induces enhanced degradation of mitochondrial
DNA-encoded proteins (Figs. 5 and 6). Although we have not directly
shown that the primary sequence of these proteins is different at the
UUR-encoded leucine residues in mutant-type cells, two independently
obtained results both demonstrate the decreased stability of these
proteins, which at least strongly suggests an alteration of their
primary structure. The pulse-chase experiments directly revealed an
elevated degradation rate (Fig. 5), whereas the same may also be
inferred from the low steady state levels (Fig. 6) in the absence of a
strong decrease of de novo protein synthesis (Figs. 3, 4,
and 6). Direct sequencing of isolated mitochondrial proteins will
provide evidence as to whether alterations in the primary structure are
indeed involved in the pathogenesis of MIDD.
We are indepted to Dr. H. Jacobs (University
of Tampere) for sharing his unpublished results. We thank Dr G. Attardi
(California Institute of Technology) for his kind gift of MERRF cybrids
and polyclonal anti-CO II antibody, Dr J. Wells (University of
Cambridge) for antibodies against human mitochondrial
elongation factor EF-Tu, and Ing L. `t Hart (Leiden University Medical
Center) for help in statistical analysis.
*
This work was supported in part by grants from the
Netherlands Organization for Scientific Research (NWO) and the
Netherlands Diabetes Foundation (DFN).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address: Clinical Chemistry Laboratory, Isala Clinics,
P. O. Box 10500, 8000 GM Zwolle, The Netherlands.
2
H. Jacobs, personal communication.
The abbreviations used are:
MIDD, maternally
inherited diabetes and deafness;
MELAS, mitochondrial myopathy,
encephalopathy, lactic acidosis, and stroke-like episodes;
MERRF, myoclonus epilepsy with ragged red fibers;
DMEM, Dulbecco's modified
Eagle's medium.
The Diabetes-associated 3243 Mutation in the Mitochondrial
tRNALeu(UUR) Gene Causes Severe Mitochondrial Dysfunction
without a Strong Decrease in Protein Synthesis Rate*
,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
°-3 cells (12). Patient V displays
the phenotype of maternally inherited diabetes and deafness. Patient A
suffers from Alport-like syndrome, which is characterized by
progressive kidney disease, sensorineural hearing loss, and maternal
inheritance (13). Diabetes also develops after transplantation and
immunosuppressive therapy with steroids but is overshadowed by the
kidney disease. Therefore, MIDD and Alport-like syndrome have in common
maternal inheritance, sensorineural deafness, and diabetes, with renal failure as a prominent characteristic for Alport-like syndrome. From
both donors we obtained fully wild-type cybrids (W6 and W7 from patient
V; W20 from patient A) as well as mutant-type cybrids (M48 and M50 from
patient V; M12, M26, and M30 from patient A) (12). Cybrids, 143B
osteosarcoma cells and B
°-3 cells were all cultured in Dulbecco's
modified Eagle's medium containing 4.5 mg/ml glucose and 110 µg/ml
pyruvate (DMEM) supplemented with 50 µg/ml uridine and 10% fetal
bovine serum (complete DMEM). For long-term culturing (maximum ~3
months), the cybrids were cultured in DMEM supplemented with 10%
dialysed fetal calf serum to preserve a high level of mitochondrial
DNA. The mitochondrial DNA copy numbers of the cybrids used were all
comparable with that of 143B cells. Cybrid cells were never cultured
for longer than about 3 months. After this period a fresh vial of cells
from the stock, stored in liquid nitrogen, was used.
, was calculated from
=
(2.3
log(n/n0))/t, where t = 2880 min and n0 and
n denote the amount of 35S in an individual
protein band following pulse and chase, respectively. Autoradiograms
were digitalized and processed using a GDS8000 gel analysis system
(Ultra Violet Products, Lambridge) for that purpose. Statistical
analysis of the decay data was performed using Student's t
test (SPSS version 7.0).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (18K):
[in a new window]
Fig. 1.
Highly reduced respiration rates of
mutant-type cybrids. Oxygen consumption of about 5 × 106 exponentially growing wild-type (VW7) or
mutant (VM50) cells was monitored in a 2-ml reaction chamber
using a Clark-type oxygen electrode. Oxygen consumption is expressed as
the percentage of oxygen consumed from the amount originally present in
the medium, i.e. ~ 0.25 mM O2.
Cells were added at t = 5 min in both cases. A
comparably low respiration rate was found in the other mutant-type
cybrids (12).

View larger version (59K):
[in a new window]
Fig. 2.
Highly reduced
leucyl-tRNALeu(UUR) levels in mutant-type cybrids.
A, steady state levels of tRNALeu(UUR) and
tRNAPhe in wild-type and mutant-type cybrids were
determined by Northern blot analysis. Each of the two labeled cDNA
probes for tRNALeu(UUR) and tRNAPhe detected a
single band corresponding to the size expected for
tRNALeu(UUR) (78 nucleotides) or tRNAPhe (74 nucleotides) in both the wild-type as well as the mutant-type cybrids.
B, the in vivo aminoacylation levels of
tRNALeu(UUR) and tRNALys in wild-type and
mutant-type cybrids were estimated by acidic high resolution Northern
blot analysis using specific 32P-labeled cDNA probes
for tRNALeu(UUR) and tRNALys, respectively. The
position of the aminoacylated and non-acylated tRNAs are indicated on
the right. In contrast to tRNALeu(UUR), the two
tRNALys species were found to be well resolved, in
agreement with Enriquez and Attardi (24). Incubation at 100 °C was
performed to enhance deacylation of aminoacyl-tRNA and to identify the
relative positions of the aminoacylated and non-acylated tRNA
species.

View larger version (61K):
[in a new window]
Fig. 3.
[35S]Methionine incorporation
into wild-type versus mutant-type cybrids.
Left, a representative result of
[35S]methionine incorporation into wild-type
versus mutant-type cybrids. The rate of mitochondrial
protein synthesis in mutant-type cybrids was very comparable with that
of wild-type cybrids with the exception of M12, which was reproducibly
lower. CO, cytochrome c oxidase subunit;
ND, NADH dehydrogenase subunit; A, ATPase
subunit. Arrowheads indicate the position of additional
protein bands in the mutant-type cybrids. Right, comparison
of MIDD and MERRF-derived mitochondrial protein synthesis
(WT, wild-type MERRF; MT, mutant-type MERRF).
After a prolonged 270-min labeling, the additional
35S-labeled protein bands as found previously in
mutant-type MERRF cybrids (7) also became visible.

View larger version (17K):
[in a new window]
Fig. 4.
[3H]Leucine incorporation into
wild-type versus mutant-type cybrids.
[3H]Leucine incorporation into trichloroacetic
acid-precipitable material appears to be highly dependent on cell
density. Density is expressed as µg of whole-cell
protein/cm2 of tissue culture area available and
incorporation as cpm/µg of whole-cell protein; 30 µg/cm2 corresponds to ~50% confluency. The data
obtained for wild-type cybrids (
) and mutant-type cybrids (
),
respectively, were fit to a straight line by using a least-squares
fitting procedure. Linear regression analysis of these data revealed
that mutant-type cybrids incorporated significantly (p < 0.01) less [3H]Leu than wild-type cybrids.

View larger version (19K):
[in a new window]
Fig. 5.
Enhanced degradation in mutant-type
cybrids. The decay rate constant,
, of individual
mitochondrially encoded proteins was estimated from pulse-chase
experiments as detailed under "Experimental Procedures." Because
measurements are based on equal protein load, the degradation rate is
somewhat underestimated in the slower growing mutant cybrids. Well
resolved and strongly labeled protein bands were selected, except for
cytochrome c oxidase subunit II (COII), which represents
rather the sum of COII and ATPase subunit 6 (A6) degradation. Note that
the stability of the selected proteins is remarkably comparable, with
half-lives estimated to be ~50 h. Open bars, wild-type;
filled bars, mutant-type cybrids. Results are expressed as
means ± S.D. When treated as one group, the mutant-type proteins
were found to degrade significantly (p < 0.01) faster
than wild-type proteins. When treated separately, only the differences
of COII and A8 reached statistical significance (p < 0.05). A similar loss of stability of mutant-type cytochrome
c oxidase subunit I was also observable after its
immunoprecipitation from M50 versus W7 extracts,
respectively. NDII, NADH dehydrogenase subunit II.
°-3 cells. Thus, the specific reduction of
mitochondrially encoded proteins seems to reflect the increased rate of
protein degradation.

View larger version (31K):
[in a new window]
Fig. 6.
Lowered levels of mitochondrially encoded
proteins in mutant-type cybrids. Right, Western blots
of mitochondrially encoded proteins cytochrome c oxidase
subunit I (CO I) and II (CO II) versus
the nuclear encoded protein CO IV and protein synthesis
elongation factor EF-Tu. Comparable results were
obtained with a polyclonal antiserum against CO II. Left,
for comparison, the rate of synthesis of CO I and CO II, as reflected
by immunoprecipitation from [35S]methionine-labeled W7
and M50 cybrids, is shown. This result indicates that the two
monoclonal antibodies recognize the wild-type and mutant-type CO I and
CO II proteins equally well.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
To whom correspondence should be addressed. Tel: 31-71-5276296;
Fax: 31-71-5276284; E-mail:
G.M.C.Janssen@mcb.medfac.leidenuniv.nl.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Goto, Y.,
Nonaka, I.,
and Horai, S.
(1990)
Nature
348,
651-653[CrossRef][Medline]
[Order article via Infotrieve]
2.
Shoffner, J. M.,
Lott, M. T.,
Lezza, A. M.,
Seibel, P.,
Ballinger, S. W.,
and Wallace, D. C.
(1990)
Cell
61,
931-937[CrossRef][Medline]
[Order article via Infotrieve]
3.
Van den Ouweland, J. M. W.,
Lemkes, H. H. P. J.,
Ruitenbeek, W.,
Sandkuijl, L. A.,
de Vijlder, M. F.,
Struijvenberg, P. A. A.,
van de Kamp, J. J. P.,
and Maassen, J. A.
(1992)
Nat. Genet.
1,
368-371[CrossRef][Medline]
[Order article via Infotrieve]
4.
Wallace, D. C.
(1992)
Annu. Rev. Biochem.
61,
1175-1212[CrossRef][Medline]
[Order article via Infotrieve]
5.
Larsson, N. G.,
and Clayton, D. A.
(1995)
Annu. Rev. Genet.
29,
151-178[CrossRef][Medline]
[Order article via Infotrieve]
6.
Grossman, L. I.,
and Shoubridge, E. A.
(1996)
Bioassays
18,
983-991[CrossRef][Medline]
[Order article via Infotrieve]
7.
Enriquez, J. A.,
Chomyn, A.,
and Attardi, G.
(1995)
Nat. Genet.
10,
47-55[CrossRef][Medline]
[Order article via Infotrieve]
8.
Chomyn, A.,
Martinuzzi, A.,
Yoneda, M.,
Daga, A.,
Hurko, O.,
Johns, D.,
Lai, S. T.,
Nonaka, I.,
Angelini, C.,
and Attardi, G.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
4221-4225 9.
King, M. P.,
Koga, Y.,
Davidson, M.,
and Schon, E. A.
(1992)
Mol. Cell. Biol.
12,
480-490 10.
Kadowaki, T.,
Kadowaki, H.,
Mori, Y.,
Tobe, K.,
Sakuta, R.,
Suzuki, Y.,
Tanabe, Y.,
Sakura, H.,
Awata, T.,
and Goto, Y.
(1994)
N. Engl. J. Med.
330,
962-968 11.
Maassen, J. A.,
and Kadowaki, T.
(1996)
Diabetologia
39,
375-382[Medline]
[Order article via Infotrieve]
12.
van den Ouweland, J. M. W.,
Maechler, P.,
Wolheim, C. B.,
Attardi, G.,
and Maassen, J. A.
(1999)
Diabetologia
42,
485-492[CrossRef][Medline]
[Order article via Infotrieve]
13.
Jansen, J. J.,
Maassen, J. A.,
van der Woude, F. J.,
Lemmink, H. A.,
van den Ouweland, J. M.,
't Hart, L. M.,
Smeets, H. J.,
Bruijn, J. A.,
and Lemkes, H. H.
(1997)
J. Am. Soc. Nephrol.
8,
1118-1124[Abstract]
14.
King, M. P.,
and Attardi, G.
(1989)
Science
246,
500-503 15.
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159[Medline]
[Order article via Infotrieve]
16.
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
17.
Varshney, U.,
Lee, C.-P.,
and RajBhandary, U. L.
(1991)
J. Biol. Chem.
266,
24712-24718 18.
Chomyn, A.,
Meola, G.,
Bresolin, N.,
Lai, S. T.,
Scarlato, G.,
and Attardi, G.
(1991)
Mol. Cell. Biol.
11,
2236-2244 19.
Janssen, G. M. C.,
Maassen, J. A.,
and Möller, W.
(1990)
in
Ribosomes and Protein Synthesis
(Spedding, G., ed)
, pp. 51-68, Oxford University Press, New York
20.
Chomyn, A.
(1996)
Methods Enzymol.
264,
197-211[Medline]
[Order article via Infotrieve]
21.
Towbin, H.,
Staehelin, T.,
and Gordon, J.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
76,
4350-4354 22.
Kessler, S. W.
(1981)
Methods Enzymol.
73,
442-459[Medline]
[Order article via Infotrieve]
23.
Lanker, S.,
Bushman, J. L.,
Hinnebush, A. G.,
Trachsel, H.,
and Mueller, P. P.
(1992)
Cell
70,
647-657[CrossRef][Medline]
[Order article via Infotrieve]
24.
Enriquez, J. A.,
and Attardi, G.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
8300-8305 25.
van den Ouweland, J. M. W.
(1994)
A New Subtype of Non-insulin-dependent Diabetes Mellitus Is Associated with a Mitochondrial Gene Mutation.Ph.D. thesis
, Leiden University
26.
Flier, A.,
Reichmann, H.,
and Seibel, P.
(1997)
J. Biol. Chem.
272,
27189-27196 27.
El Meziane, A.,
Lehtinen, S. K.,
Hance, N.,
Nijtmans, L. G. J.,
Dunbar, D.,
Holt, I. J.,
and Jacobs, H. T.
(1998)
Nat. Genet.
18,
350-353[CrossRef][Medline]
[Order article via Infotrieve]
28.
Negrutskii, B. S.,
and Deutscher, M. P.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
4991-4995 29.
Rossmanith, W.,
and Karwan, R. M.
(1998)
FEBS Lett.
443,
269-274
30.
King, M. P.,
and Attardi, G.
(1993)
J. Biol. Chem.
268,
10228-10237 31.
Kennel, D.,
and Riezman, H.
(1977)
J. Mol. Biol.
114,
1-21[CrossRef][Medline]
[Order article via Infotrieve]
32.
Ogilvie, A.,
Huschka, U.,
and Kersten, W.
(1979)
Biochim. Biophys. Acta
565,
293-304[Medline]
[Order article via Infotrieve]
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
S. G. Park, P. Schimmel, and S. Kim Aminoacyl tRNA synthetases and their connections to disease PNAS, August 12, 2008; 105(32): 11043 - 11049. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M.C. Janssen, P. J. Hensbergen, F. J. van Bussel, C. I.A. Balog, J. A. Maassen, A. M. Deelder, and A. K. Raap The A3243G tRNALeu(UUR) mutation induces mitochondrial dysfunction and variable disease expression without dominant negative acting translational defects in complex IV subunits at UUR codons Hum. Mol. Genet., October 15, 2007; 16(20): 2472 - 2481. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Maniura-Weber, M. Helm, K. Engemann, S. Eckertz, M. Mollers, M. Schauen, A. Hayrapetyan, J.-C. von Kleist-Retzow, R. N. Lightowlers, L. A. Bindoff, et al. Molecular dysfunction associated with the human mitochondrial 3302A>G mutation in the MTTL1 (mt-tRNALeu(UUR)) gene Nucleic Acids Res., December 2, 2006; 34(22): 6404 - 6415. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. ROY, L. M. WITTENHAGEN, and S. O. KELLEY Structural probing of a pathogenic tRNA dimer RNA, March 1, 2005; 11(3): 254 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Maassen, Leen. M. 't Hart, E. van Essen, R. J. Heine, G. Nijpels, R. S. Jahangir Tafrechi, A. K. Raap, G. M.C. Janssen, and H. H.P.J. Lemkes Mitochondrial Diabetes: Molecular Mechanisms and Clinical Presentation Diabetes, February 1, 2004; 53(90001): S103 - 109. [Abstract] [Full Text] |
||||
![]() |
H. T. Jacobs Disorders of mitochondrial protein synthesis Hum. Mol. Genet., October 15, 2003; 12(90002): R293 - 301. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Tryoen-Toth, S. Richert, B. Sohm, M. Mine, C. Marsac, A. Van Dorsselaer, E. Leize, and C. Florentz Proteomic Consequences of a Human Mitochondrial tRNA Mutation beyond the Frame of Mitochondrial Translation J. Biol. Chem., June 27, 2003; 278(27): 24314 - 24323. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Gu, C. Wang, C. M. Roifman, and A. Cohen Role of MHC Class I in Immune Surveillance of Mitochondrial DNA Integrity J. Immunol., April 1, 2003; 170(7): 3603 - 3607. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ohkubo, A. Yamano, M. Nagashima, Y. Mori, K. Anzai, Y. Akehi, R. Nomiyama, T. Asano, A. Urae, and J. Ono Mitochondrial Gene Mutations in the tRNALeu(UUR) Region and Diabetes: Prevalence and Clinical Phenotypes in Japan Clin. Chem., September 1, 2001; 47(9): 1641 - 1648. [Abstract] [Full Text] [PDF] |
||||
![]() |
, J. M. v. , R. , , , G. , H. , , J. , and A. Simultaneous A8344G heteroplasmy and mitochondrial DNA copy number quantification in Myoclonus Epilepsy and Ragged-Red Fibers (MERRF) syndrome by a multiplex Molecular Beacon based real-time fluorescence Nucleic Acids Res., February 1, 2001; 29(3): e13 - e13. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yasukawa, N. Hino, T. Suzuki, K. Watanabe, T. Ueda, and S. Ohta A pathogenic point mutation reduces stability of mitochondrial mutant tRNAIle Nucleic Acids Res., October 1, 2000; 28(19): 3779 - 3784. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. T. Jacobs and I. J. Holt The np 3243 MELAS mutation: damned if you aminoacylate, damned if you don't Hum. Mol. Genet., March 1, 2000; 9(4): 463 - 465. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Chomyn, J. A. Enriquez, V. Micol, P. Fernandez-Silva, and G. Attardi The Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like Episode Syndrome-associated Human Mitochondrial tRNALeu(UUR) Mutation Causes Aminoacylation Deficiency and Concomitant Reduced Association of mRNA with Ribosomes J. Biol. Chem., June 16, 2000; 275(25): 19198 - 19209. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||